PepEasyWiki

Cycling

Educational only — not medical advice. See Disclaimer.

“Cycling” refers to taking a compound for a defined period (“on”) and then deliberately pausing (“off”) before any further use. It is one of the most common conventions in the peptide community — and also one of the most weakly evidenced. This page explains what the term means, the reasons people give for cycling, and why most specific protocols are better understood as convention and analogy than as established science.

What cycling means

A cycle has two phases:

  • On-cycle — the period of active use (e.g. “8 weeks”).
  • Off-cycle — a break with no use (e.g. “4 weeks off”).

People describe cycles in shorthand like “8 weeks on, 4 weeks off.” The specific numbers vary widely between communities, compounds, and individuals.

Why people say they cycle

Commonly cited rationales — presented as claims, not endorsements:

  • Receptor sensitivity / tolerance. The idea that continuous stimulation of a receptor pathway may blunt the response over time, and that a break may restore sensitivity. The strength of this varies a lot by mechanism and is often assumed rather than demonstrated for a given peptide.
  • Avoiding suppression of natural pathways. For compounds that influence hormonal axes (e.g. GH secretagogues like MK-677), some argue that breaks reduce the chance of dampening the body’s own signaling.
  • Limiting cumulative exposure. Keeping total exposure lower as a precaution, particularly where long-term safety data are absent.
  • Reassessing need and effect. An off-cycle is a natural point to check whether benefits persist and to review labs (see Bloodwork & Monitoring).

Common conventions (and their weak basis)

Numbers vary and are mostly anecdotal

You will see many “standard” cycle lengths. They are largely borrowed conventions — often adapted from bodybuilding/anabolic culture or from a compound’s Half-Life & Pharmacokinetics — rather than results from controlled human trials.

  • Healing/repair peptides (e.g. BPC-157): frequently run for a finite “course” tied to a specific injury or goal, then stopped — closer to a defined treatment window than an indefinite cycle.
  • GH secretagogues (e.g. MK-677): “on/off” framing is common, justified by sensitivity and hormonal-axis arguments; the optimal pattern is not well established.
  • Metabolic/GLP-1 class (Semaglutide): clinically these are often used continuously under supervision rather than “cycled,” and abrupt stops can have their own effects (e.g. appetite/weight rebound) — a clinician’s domain.

"Cycling" is not a safety guarantee

Taking breaks does not neutralize the risks of an unstudied or contaminated compound, and it does not substitute for medical supervision. A cycle length found in a forum is a convention, not a validated dosing schedule. Whether to use anything at all — and on what schedule — is a clinical decision.

A more defensible framing

Rather than copying a number, the more conservative reasoning many take is:

  1. Define a specific goal and a time-limited plan with a clear endpoint.
  2. Establish baseline labs before starting and recheck during/after (see Bloodwork & Monitoring).
  3. Treat the off-cycle as a checkpoint to evaluate effect, side effects, and whether to continue at all.
  4. Involve a clinician in the decision, especially for anything affecting hormones or metabolism.

← Home · See the Disclaimer

Graph View